{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Servetto A"],"pubmed_abstract":["Background
In addition to improving survival outcomes, new oncology treatments should lead to amelioration of patients' quality of life (QoL). Herein, we examined whether QoL results correlated with PFS and OS outcomes in phase III randomized controlled trials (RCTs) investigating new systemic treatments in metastatic non-small cell lung cancer (NSCLC).Methods
The systematic search of PubMed was conducted in October 2022. We identified 81 RCTs testing novel drugs in metastatic NSCLC and published in the English language in a PubMed-indexed journal between 2012 and 2021. Only trials reporting QoL results and at least one survival outcome between OS and PFS were selected. For each RCT, we assessed whether global QoL was \"superior,\" \"inferior,\" or with \"non-statistically signi"],"journal":["BMC medicine"],"pagination":["234"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10318754"],"repository":["biostudies-literature"],"pubmed_title":["Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes."],"pmcid":["PMC10318754"],"pubmed_authors":["Salomone F","Formisano L","Santaniello A","Servetto A","Paratore C","Viscardi G","Napolitano F","Di Costanzo F","Bianco R","Di Maio M"],"additional_accession":[]},"is_claimable":false,"name":"Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes.","description":"Background
In addition to improving survival outcomes, new oncology treatments should lead to amelioration of patients' quality of life (QoL). Herein, we examined whether QoL results correlated with PFS and OS outcomes in phase III randomized controlled trials (RCTs) investigating new systemic treatments in metastatic non-small cell lung cancer (NSCLC).Methods
The systematic search of PubMed was conducted in October 2022. We identified 81 RCTs testing novel drugs in metastatic NSCLC and published in the English language in a PubMed-indexed journal between 2012 and 2021. Only trials reporting QoL results and at least one survival outcome between OS and PFS were selected. For each RCT, we assessed whether global QoL was \"superior,\" \"inferior,\" or with \"non-statistically signi","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Jul","modification":"2025-04-26T18:47:04.442Z","creation":"2025-04-06T15:54:02.168Z"},"accession":"S-EPMC10318754","cross_references":{"pubmed":["37400832"],"doi":["10.1186/s12916-023-02953-0"]}}